<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>IQ-AI ( (GB:IBAI) ) has provided an update. Imaging Biometrics Limited has corrected an error in its recent notice regarding a proposed share sub-division ahead of its upcoming Annual General Meeting in Jersey on 3 June 2026. The company clarified that each ordinary share of £0.01 will be sub-divided into one ordinary share of £0.005, with the total number of shares in issue remaining unchanged at 246,709,789, and confirmed that all other AGM resolutions are unaffected. The updated AGM documentation, including the corrected notice and proxy form, will be made available on the company’s website for shareholders. While the change is technical in nature and does not alter shareholders’ aggregate holdings, the clarification removes potential confusion around the capital structure as the group continues to develop its neuroimaging software and organ-on-a-chip offerings in global healthcare and research markets. Spark’s Take on IBAI Stock According to Spark, TipRanks’ AI Analyst, IBAI is a Neutral. The score is driven primarily by weak financial performance (persistent losses and ongoing cash burn), reinforced by bearish technicals with the stock trading well below key moving averages. Low reported leverage helps reduce balance-sheet risk, but valuation is constrained by negative earnings and no dividend yield data. To see Spark’s full report on IBAI stock, click here. More about IQ-AI Imaging Biometrics Limited is an LSE-listed healthcare technology group specialising in quantitative neuroimaging software and organ-on-a-chip technologies. Its main subsidiary, Imaging Biometrics LLC, provides advanced MRI analysis tools for brain tumour assessment, distributed globally through partners including GE HealthCare, while Kirkstall Limited offers the Quasi Vivo organ-on-a-chip platform for pharmaceutical and toxicology research. Average Trading Volume: 537,715 Technical Sentiment Signal: Strong Sell Current Market Cap: £1.42M For an in-depth examination of IBAI stock, go to TipRanks’ Overview page.</div>

516930

513060

Imaging Biometrics Limited has corrected an error regarding its proposed share sub-division ahead of the Annual General Meeting on June 3, 2026. Each ordinary share of £0.01 will now be sub-divided into one ordinary share of £0.005, with the total shares remaining at 246,709,789. The AGM resolutions remain unaffected, and updated documentation will be available on the company’s website. Spark’s AI Analyst rates IBAI stock as Neutral, citing weak financial performance and bearish technicals, despite low leverage reducing balance-sheet risk.

Tip Ranks

Minsheng Royal CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

Bosera Hang Seng Health Care ETF(QDII)

SPDR S&P Biotech

iShares US Medical Devices

First Trust NYSE Arca Biotech Index Fd

E Fund CSI Biotechnology Theme ETF

VanEck Biotech ETF

Hwabao WP CSI Medical Service ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Proshares UltraShort Nasdaq Biotech

ChinaAMC CSI Biotechnology Theme ETF

SPDR S&P Health Equip

iShares Biotechnology ETF

ALPS Medical Breakthrough

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI Biotechnology Theme ETF

GE HealthCare Tech

Imaging Biometrics Corrects AGM Share Sub-division Terms Ahead of June Meeting